[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002077017A3 - Medical uses of intercellular communication facilitating compounds - Google Patents

Medical uses of intercellular communication facilitating compounds Download PDF

Info

Publication number
WO2002077017A3
WO2002077017A3 PCT/US2002/005773 US0205773W WO02077017A3 WO 2002077017 A3 WO2002077017 A3 WO 2002077017A3 US 0205773 W US0205773 W US 0205773W WO 02077017 A3 WO02077017 A3 WO 02077017A3
Authority
WO
WIPO (PCT)
Prior art keywords
medical uses
intercellular communication
facilitating compounds
communication facilitating
peptides
Prior art date
Application number
PCT/US2002/005773
Other languages
French (fr)
Other versions
WO2002077017A2 (en
Inventor
Bjarne Due Larsen
Jorgen Soberg Petersen
Eddie Meier
Anne Louise Kjolbye
Niklas Rye Jorgensen
Morten Schak Nielsen
Niels-Henrik Holstein-Rathlou
James B Martins
Original Assignee
Zealand Pharma As
Bjarne Due Larsen
Jorgen Soberg Petersen
Eddie Meier
Anne Louise Kjolbye
Niklas Rye Jorgensen
Morten Schak Nielsen
Niels-Henrik Holstein-Rathlou
James B Martins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/792,286 external-priority patent/US7250397B2/en
Priority claimed from PCT/DK2001/000127 external-priority patent/WO2001062775A2/en
Priority to JP2002576275A priority Critical patent/JP2005506295A/en
Priority to NZ527571A priority patent/NZ527571A/en
Priority to EP02723240A priority patent/EP1370276B1/en
Priority to DK02723240.4T priority patent/DK1370276T3/en
Priority to AT02723240T priority patent/ATE497967T1/en
Priority to MXPA03007537A priority patent/MXPA03007537A/en
Priority to IL15744702A priority patent/IL157447A0/en
Priority to EA200300912A priority patent/EA007792B1/en
Application filed by Zealand Pharma As, Bjarne Due Larsen, Jorgen Soberg Petersen, Eddie Meier, Anne Louise Kjolbye, Niklas Rye Jorgensen, Morten Schak Nielsen, Niels-Henrik Holstein-Rathlou, James B Martins filed Critical Zealand Pharma As
Priority to DE60239126T priority patent/DE60239126D1/en
Priority to CA2439101A priority patent/CA2439101C/en
Priority to KR10-2003-7011099A priority patent/KR20040004538A/en
Priority to BR0207476-1A priority patent/BR0207476A/en
Priority to AU2002254033A priority patent/AU2002254033B2/en
Publication of WO2002077017A2 publication Critical patent/WO2002077017A2/en
Priority to NO20033641A priority patent/NO20033641L/en
Priority to US10/646,294 priority patent/US7585839B2/en
Publication of WO2002077017A3 publication Critical patent/WO2002077017A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.
PCT/US2002/005773 2000-02-23 2002-02-22 Medical uses of intercellular communication facilitating compounds WO2002077017A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR0207476-1A BR0207476A (en) 2001-02-22 2002-02-22 Use of a compound and pharmaceutical composition
AU2002254033A AU2002254033B2 (en) 2001-02-22 2002-02-22 Medical uses of intercellular communication facilitating compounds
DE60239126T DE60239126D1 (en) 2001-02-22 2002-02-22 INTERCELLULAR COMMUNICATION SIMPLIFIED CONNECTIONS AND THEIR MEDICAL USES
EP02723240A EP1370276B1 (en) 2001-02-22 2002-02-22 Intercellular communication facilitating compounds and their medical use
DK02723240.4T DK1370276T3 (en) 2001-02-22 2002-02-22 Intracellular communication-facilitating compounds and their medical applications
AT02723240T ATE497967T1 (en) 2001-02-22 2002-02-22 INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS AND THEIR MEDICAL USES
MXPA03007537A MXPA03007537A (en) 2001-02-22 2002-02-22 New medical uses of intercellular communication facilitating compounds.
IL15744702A IL157447A0 (en) 2001-02-22 2002-02-22 New medical uses of intercellular communication facilitating compounds
EA200300912A EA007792B1 (en) 2001-02-22 2002-02-22 Medical uses of intercellular communication facilitating compounds
JP2002576275A JP2005506295A (en) 2001-02-22 2002-02-22 Novel medicinal use of intercellular communication promoting compounds
NZ527571A NZ527571A (en) 2001-02-22 2002-02-22 peptides including novel antiarrhythmic peptides of linear or cyclic structure having improved stability in vitro and/or in vivo, to compositions comprising said peptides, and to uses of said peptides for the preparation of medicaments.
CA2439101A CA2439101C (en) 2001-02-22 2002-02-22 New medical uses of intercellular communication facilitating compounds
KR10-2003-7011099A KR20040004538A (en) 2001-08-23 2002-02-22 New medical uses of intercellular communication facilitating compounds
NO20033641A NO20033641L (en) 2001-02-22 2003-08-15 New medical applications of intercellular communication facilitating compounds
US10/646,294 US7585839B2 (en) 2000-02-23 2003-08-22 Medical uses of intercellular communication facilitating compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/792,286 US7250397B2 (en) 2000-02-23 2001-02-22 Antiarrhythmic peptides
DKPCT/DK01/00127 2001-02-22
PCT/DK2001/000127 WO2001062775A2 (en) 2000-02-23 2001-02-22 Novel antiarrhythmic peptides
US09/792,286 2001-02-22
US31447001P 2001-08-23 2001-08-23
US60/314,470 2001-08-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/646,294 Continuation US7585839B2 (en) 2000-02-23 2003-08-22 Medical uses of intercellular communication facilitating compounds

Publications (2)

Publication Number Publication Date
WO2002077017A2 WO2002077017A2 (en) 2002-10-03
WO2002077017A3 true WO2002077017A3 (en) 2003-10-09

Family

ID=27222186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005773 WO2002077017A2 (en) 2000-02-23 2002-02-22 Medical uses of intercellular communication facilitating compounds

Country Status (6)

Country Link
EP (1) EP1370276B1 (en)
JP (1) JP2005506295A (en)
AT (1) ATE497967T1 (en)
IL (1) IL157447A0 (en)
MX (1) MXPA03007537A (en)
WO (1) WO2002077017A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US7153822B2 (en) * 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
NZ540155A (en) * 2002-11-25 2006-11-30 Zealand Pharma As Peptides that modulate gap junction intercellular communication (GJIC).for use in the treatment or prevention of pathologies associated with impaired GJIC
WO2005061437A2 (en) * 2003-12-23 2005-07-07 Wyeth Isopeptide gap junction modulators
DE102005005270A1 (en) * 2005-02-04 2006-08-10 Peter Heger Use of a hydroxystilbene-containing active substance combination containing resveratrol and piceatannol precursors, to prevent and/or treat diseases caused by increased serum interleukin-6 level e.g. depression
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
PT1966130E (en) 2005-12-23 2014-01-30 Zealand Pharma As Modified lysine-mimetic compounds
EP2074087A2 (en) 2006-12-21 2009-07-01 Wyeth Synthesis of pyrrolidine compounds
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators
WO2010026487A1 (en) * 2008-09-08 2010-03-11 University Of Concepcion Therapeutic methods and compositions
GB201512139D0 (en) * 2015-07-10 2015-08-19 Zealand Pharma As Methods of treatment
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2021159011A1 (en) * 2020-02-07 2021-08-12 United States Government As Represented By The Department Of Veterans Affairs Method for treating nervous system injuries using boldine and analogs thereof
CA3240515A1 (en) 2021-12-22 2023-06-29 Breye Therapeutics Aps Gap junction modulators and their use for the treatment of age-related macular degeneration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021674A1 (en) * 1995-01-14 1996-07-18 Basf Aktiengesellschaft Novel peptides, their production and use
DE19707854A1 (en) * 1997-02-27 1998-09-03 Dhein Stefan Priv Doz Dr Med New cyclic peptides used as antiarrhythmic agents
WO2001062775A2 (en) * 2000-02-23 2001-08-30 Zealand Pharma A/S Novel antiarrhythmic peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021674A1 (en) * 1995-01-14 1996-07-18 Basf Aktiengesellschaft Novel peptides, their production and use
DE19707854A1 (en) * 1997-02-27 1998-09-03 Dhein Stefan Priv Doz Dr Med New cyclic peptides used as antiarrhythmic agents
WO2001062775A2 (en) * 2000-02-23 2001-08-30 Zealand Pharma A/S Novel antiarrhythmic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DHEIN S ET AL: "THERAPEUTIC POTENTIAL OF ANTIARRHYTHMIC PEPTIDES CELLULAR COUPLING AS A NEW ANTIARRHYTHMIC TARGET", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 49, no. 6, 1995, pages 851 - 855, XP001034031, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
WO2002077017A2 (en) 2002-10-03
EP1370276B1 (en) 2011-02-09
ATE497967T1 (en) 2011-02-15
JP2005506295A (en) 2005-03-03
MXPA03007537A (en) 2005-09-30
EP1370276A2 (en) 2003-12-17
IL157447A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
EP1478322A4 (en) Beta-2'-OR 3'-HALONUCLEOSIDES
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2003000187A3 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
WO2002096272A3 (en) Absorbable implantable vaso-occlusive member
HK1048990A1 (en) Novel compounds.
GB0128996D0 (en) Organic compounds
WO2002077017A3 (en) Medical uses of intercellular communication facilitating compounds
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002257663A1 (en) Stabilization of aroma-providing components
WO2003017760A3 (en) Fungicide active substance combinations
WO2000066528A3 (en) Quinones for treatment of diseases
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
WO2002070464A3 (en) Hydrazones and their therapeutic use
WO2003037262A3 (en) Novel anit-infectives
AU2002365093A1 (en) Therapeutic compositions
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU2003212344A1 (en) Use of extracts from olive trees as anti-dandruff agents
AUPR600601A0 (en) Therapeutic compositions
WO2002089740A3 (en) Sulfonamides
EP1436279B8 (en) Chemical compounds
WO2003002084A3 (en) Fragrance and flavour compositions
WO2002078641A3 (en) Pyrrolidine sulfonamides
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002723240

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 527571

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/06410

Country of ref document: ZA

Ref document number: 157447

Country of ref document: IL

Ref document number: 200306410

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2439101

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007537

Country of ref document: MX

Ref document number: 2002576275

Country of ref document: JP

Ref document number: 2002254033

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10646294

Country of ref document: US

Ref document number: 1020037011099

Country of ref document: KR

Ref document number: 01336/DELNP/2003

Country of ref document: IN

Ref document number: 1336/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200300912

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 028074025

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002723240

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037011099

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0207476

Country of ref document: BR